• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Lepage, C
    Dahan, L
    Bouarioua, N
    Toumpanakis, C
    Legoux, J
    Le Malicot, K
    Guimbaud, R
    Smith, D
    Tougeron, D
    Lievre, A
    Cadiot, G
    Di Fiore, F
    Bouhier-Leporrier, K
    Hentic, O
    Faroux, R
    Pavel, M
    Borbath, I
    Valle, Juan W
    Rinke, A
    Scoazec, J
    Ducreux, M
    Walter, T
    Show allShow less
    Affiliation
    Department of Digestive Oncology, Burgundy Franche-Conte University, University hospital Dijon, Dijon, France
    Issue Date
    2017-03-11
    
    Metadata
    Show full item record
    Abstract
    Patients with metastatic or locally advanced, non-resectable, grade 1 or 2 well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Patients (Pts) with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (>30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.
    Citation
    Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. 2017, 49(5):568-571 Dig Liver Dis
    Journal
    Digestive and Liver Disease
    URI
    http://hdl.handle.net/10541/620324
    DOI
    10.1016/j.dld.2017.02.004
    PubMed ID
    28292641
    Type
    Article
    Language
    en
    ISSN
    1878-3562
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.dld.2017.02.004
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.
    • Authors: Lepage C, Phelip JM, Lievre A, Le-Malicot K, Dahan L, Tougeron D, Toumpanakis C, Di-Fiore F, Lombard-Bohas C, Borbath I, Coriat R, Lecomte T, Guimbaud R, Petorin C, Legoux JL, Michel P, Scoazec JY, Smith D, Walter T
    • Issue date: 2022 Nov
    • Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.
    • Authors: Pavel M, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Capdevila J, Panzuto F, Truong Thanh XM, Houchard A, Ruszniewski P
    • Issue date: 2021 Nov
    • Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    • Authors: Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P, CLARINET Investigators
    • Issue date: 2014 Jul 17
    • Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
    • Authors: Pavel M, Lahner H, Hörsch D, Rinke A, Denecke T, Koch A, Regnault B, Helbig D, Hoffmanns P, Raderer M
    • Issue date: 2024 May 3
    • Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
    • Authors: Buil-Bruna N, Dehez M, Manon A, Nguyen TX, Trocóniz IF
    • Issue date: 2016 May
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.